News

Investor's Business Daily on MSN3d

Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval

InsmedINSM stock hit a record high Tuesday after the Food and Drug Administration approved its drug, brensocatib, for ...
Medical Dialogues7h

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...
BioPharma Dive3d

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
The American Journal of Managed Care3d

Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

FDA approves first drug for chronic lung condition bronchiectasis

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...
STAT3d

Insmed’s lung disease drug approved in the U.S.

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...
Fierce Pharma3d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...
TipRanks on MSN1d

Insmed price target raised to $139 from $126 at Truist

Truist raised the firm’s price target on Insmed (INSM) to $139 from $126 and keeps a Buy rating on the shares. The firm is positive on the stock ...

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic ...
Seeking Alpha11mon

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Insmed Incorporated's Q2 2024 revenue grew by 17% year-over-year, reaching $90.3 million, driven by strong ARIKAYCE sales. The company is preparing for the U.S. launch of brensocatib in mid-2025 ...
Healio3d

FDA approves brensocatib for non-cystic fibrosis bronchiectasis

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...